BR112021025306A2 - Medicamento e seu uso para o tratamento de infecções bacterianas envolvendo biofilme - Google Patents
Medicamento e seu uso para o tratamento de infecções bacterianas envolvendo biofilmeInfo
- Publication number
- BR112021025306A2 BR112021025306A2 BR112021025306A BR112021025306A BR112021025306A2 BR 112021025306 A2 BR112021025306 A2 BR 112021025306A2 BR 112021025306 A BR112021025306 A BR 112021025306A BR 112021025306 A BR112021025306 A BR 112021025306A BR 112021025306 A2 BR112021025306 A2 BR 112021025306A2
- Authority
- BR
- Brazil
- Prior art keywords
- bacterial infections
- treatment
- infections involving
- drug
- biofilm
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- HFYMDQMXVPJNTH-VQHVLOKHSA-N afabicin Chemical compound OP(=O)(O)OCN1C(=O)CCC2=CC(/C=C/C(=O)N(CC3=C(C4=CC=CC=C4O3)C)C)=CN=C21 HFYMDQMXVPJNTH-VQHVLOKHSA-N 0.000 abstract 2
- 229950006578 afabicin Drugs 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 108010013198 Daptomycin Proteins 0.000 abstract 1
- 108010015899 Glycopeptides Proteins 0.000 abstract 1
- 102000002068 Glycopeptides Human genes 0.000 abstract 1
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 abstract 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 1
- 229960005484 daptomycin Drugs 0.000 abstract 1
- 229940041028 lincosamides Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
afabicina para uso no tratamento de infecções bacterianas envolvendo biofilme. a presente invenção refere-se ao uso da afabicina em um método de tratamento de infeções bacterianas envolvendo biofilme que contém bactérias estafilococos, em que o método compreende administrar ao paciente a ababicina em combinação com pelo menos outro agente selecionado dentre lipopeptídeos, glicopeptídeos e lincosamidas, como daptomicina e/ou vancomicina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19180281 | 2019-06-14 | ||
| PCT/EP2020/066305 WO2020249731A1 (en) | 2019-06-14 | 2020-06-12 | Afabicin for use for treating bacterial infections involving biofilm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021025306A2 true BR112021025306A2 (pt) | 2022-02-01 |
| BR112021025306A8 BR112021025306A8 (pt) | 2022-09-20 |
Family
ID=66867028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025306A BR112021025306A8 (pt) | 2019-06-14 | 2020-06-12 | Medicamento e seu uso para o tratamento de infecções bacterianas envolvendo biofilme |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230126947A1 (pt) |
| EP (1) | EP3982975A1 (pt) |
| JP (1) | JP7418475B2 (pt) |
| KR (1) | KR20220020963A (pt) |
| CN (1) | CN113939306A (pt) |
| AU (1) | AU2020293635A1 (pt) |
| BR (1) | BR112021025306A8 (pt) |
| CA (1) | CA3139942A1 (pt) |
| CL (1) | CL2021003317A1 (pt) |
| EA (1) | EA202290048A1 (pt) |
| IL (1) | IL288861A (pt) |
| MA (1) | MA56184A (pt) |
| MX (1) | MX2021015513A (pt) |
| SG (1) | SG11202113174SA (pt) |
| WO (1) | WO2020249731A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003673B2 (en) * | 2005-05-31 | 2011-08-23 | Cubist Pharmaceuticals, Inc. | Daptomycin for the treatment of biofilm and catheter salvage |
| NZ702695A (en) | 2012-06-19 | 2015-10-30 | Debiopharm Int Sa | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
| FR3017294B1 (fr) | 2014-02-07 | 2021-10-01 | Atlangram | Nanoparticules lipidiques comprenant un antibiotique et leurs utilisations en therapie |
| US10751351B2 (en) * | 2016-02-26 | 2020-08-25 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
-
2020
- 2020-06-12 KR KR1020227001532A patent/KR20220020963A/ko active Search and Examination
- 2020-06-12 WO PCT/EP2020/066305 patent/WO2020249731A1/en active Application Filing
- 2020-06-12 EP EP20733912.8A patent/EP3982975A1/en active Pending
- 2020-06-12 EA EA202290048A patent/EA202290048A1/ru unknown
- 2020-06-12 AU AU2020293635A patent/AU2020293635A1/en active Pending
- 2020-06-12 BR BR112021025306A patent/BR112021025306A8/pt unknown
- 2020-06-12 US US17/618,882 patent/US20230126947A1/en active Pending
- 2020-06-12 MA MA056184A patent/MA56184A/fr unknown
- 2020-06-12 CA CA3139942A patent/CA3139942A1/en active Pending
- 2020-06-12 MX MX2021015513A patent/MX2021015513A/es unknown
- 2020-06-12 SG SG11202113174SA patent/SG11202113174SA/en unknown
- 2020-06-12 JP JP2021572638A patent/JP7418475B2/ja active Active
- 2020-06-12 CN CN202080042971.6A patent/CN113939306A/zh active Pending
-
2021
- 2021-12-09 IL IL288861A patent/IL288861A/en unknown
- 2021-12-13 CL CL2021003317A patent/CL2021003317A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220020963A (ko) | 2022-02-21 |
| CL2021003317A1 (es) | 2022-09-20 |
| MX2021015513A (es) | 2022-04-20 |
| JP2022535598A (ja) | 2022-08-09 |
| MA56184A (fr) | 2022-04-20 |
| IL288861A (en) | 2022-02-01 |
| BR112021025306A8 (pt) | 2022-09-20 |
| US20230126947A1 (en) | 2023-04-27 |
| EA202290048A1 (ru) | 2022-03-10 |
| WO2020249731A1 (en) | 2020-12-17 |
| SG11202113174SA (en) | 2021-12-30 |
| EP3982975A1 (en) | 2022-04-20 |
| AU2020293635A1 (en) | 2022-01-27 |
| CN113939306A (zh) | 2022-01-14 |
| JP7418475B2 (ja) | 2024-01-19 |
| CA3139942A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vassallo et al. | Antimicrobial lock therapy in central-line associated bloodstream infections: a systematic review | |
| BRPI1012219B8 (pt) | produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina | |
| Malizos et al. | Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry | |
| BR112018002227A2 (pt) | composições com potencializadores de permeação para administração de fármaco | |
| SG10201811361XA (en) | Treatment of polybacterials infections | |
| BR112022012514A2 (pt) | Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas | |
| BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
| CL2012003266A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana. | |
| BR112014027842A2 (pt) | bacteriófago lisina e combinações de antibióticos contra bactérias gram-positivas | |
| BR112014027818A2 (pt) | prevenção, ruptura e tratamento do biofilme com a lisina bacteriófaga | |
| BR112015029367A2 (pt) | terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas | |
| BRPI0916885B8 (pt) | composição farmacêutica | |
| BR112016006428A2 (pt) | anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, métodos para tratamento e/ou profilaxia de infecção por pseudomona e para produzir um anticorpo, agente de diagnóstico para infecção por pseudomona, kit de detecção para pseudomonas aeruginosa, polinucleotídeo, vetor, e, célula hospedeira transformada | |
| Jennings et al. | Antibiotic-loaded phosphatidylcholine inhibits staphylococcal bone infection | |
| BR112017006406A2 (pt) | composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico | |
| BR112015026193B8 (pt) | Composição farmacêutica, método para formular uma composição farmacêutica, uso da composição farmacêutica, método para inibir a formação de biofilme em uma superfície, e, artigo fabricado para curativo | |
| Ozturk et al. | Effects of vancomycin, daptomycin, and tigecycline on coagulase-negative staphylococcus biofilm and bacterial viability within biofilm: an in vitro biofilm model | |
| CR20230164A (es) | Compuestos fosfolípidos y usos de estos | |
| BR112021024845A2 (pt) | Combinação para o tratamento de infecções causadas por mycoplasma genitalium | |
| BR112019024549A2 (pt) | compostos derivados de glicopeptídeo e usos dos mesmos | |
| BR112021017550A2 (pt) | Métodos de tratamento da amiloidose al | |
| BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
| MX2020012543A (es) | Diltiazem para usarse en el tratamiento de infecciones microbianas. | |
| Mohamad et al. | Prosthetic joint infections due to coagulase-negative staphylococci | |
| BR112021025306A2 (pt) | Medicamento e seu uso para o tratamento de infecções bacterianas envolvendo biofilme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: DEBIOPHARM INTERNATIONAL S.A. (CH) |